Isoproterenol
Duo-medihaler, Isoproterenol, Medihaler-iso, Norisodrine (isoproterenol) is a small molecule pharmaceutical. Isoproterenol was first approved as Mucomyst w/ isoproterenol on 1982-01-01. It is used to treat adams-stokes syndrome, bradycardia, heart arrest, hemorrhagic shock, and low cardiac output amongst others in the USA. The pharmaceutical is active against beta-2 adrenergic receptor and beta-1 adrenergic receptor. In addition, it is known to target beta-3 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Isoproterenol (discontinued: Aerolone, Isoproterenol, Isuprel, Norisodrine, Norisodrine aerotrol, Vapo-iso)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Isoproterenol sulfate
Isoproterenol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ISOPROTERENOL HYDROCHLORIDE | 3M | N-010375 DISCN | 1982-01-01 | 1 products |
| NORISODRINE AEROTROL | Abbott Biotherapeutics | N-016814 DISCN | 1982-01-01 | 1 products |
| ISUPREL | Bausch Health Companies | N-010515 DISCN | 1982-01-01 | 1 products, RLD |
| VAPO-ISO | Fisons | N-016813 DISCN | 1982-01-01 | 1 products |
| AEROLONE | Eli Lilly | N-007245 DISCN | 1982-01-01 | 1 products |
| ISUPREL | Sanofi | N-006327 DISCN | 1982-01-01 | 2 products |
| ISUPREL | Sanofi | N-006328 DISCN | 1982-01-01 | 2 products |
| ISUPREL | Sanofi | N-011178 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Isoproterenol hydrochloride
+
Phenylephrine bitartrate
Acetylcysteine
+
Isoproterenol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MUCOMYST W/ ISOPROTERENOL | Mead Johnson Nutrition | N-017366 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| isoproterenol | ANDA | 2024-01-14 |
| isoproterenol hydrochloride | ANDA | 2025-07-16 |
Indications
FDA
EMA
Show 13 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01C: Cardiac stimulants excl. cardiac glycosides
— C01CA: Adrenergic and dopaminergic cardiac stimulants
— C01CA02: Isoprenaline
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AB: Non-selective beta-adrenoreceptor agonist inhalants
— R03AB02: Isoprenaline
— R03AK: Adrenergics inhalants in combination with corticosteroids or other drugs, excl. anticholinergics
— R03AK02: Isoprenaline and other drugs for obstructive airway diseases
— R03C: Adrenergics for systemic use
— R03CB: Non-selective beta-adrenoreceptor agonists for systemic use
— R03CB01: Isoprenaline
— R03CB51: Isoprenaline, combinations
HCPCS
Code | Description |
|---|---|
| J7657 | Isoproterenol hcl, inhalation solution, compounded product, administered through dme, concentrated form, per milligram |
| J7658 | Isoproterenol hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per milligram |
| J7659 | Isoproterenol hcl, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
| J7660 | Isoproterenol hcl, inhalation solution, compounded product, administered through dme, unit dose form, per milligram |
Clinical
Clinical Trials
1196 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fallopian tube neoplasms | D005185 | — | — | — | 3 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | 2 | 2 | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 2 | — | — | — | 2 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 2 | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 1 | — | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 1 | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 1 |
| Neoadjuvant therapy | D020360 | — | — | — | 1 | — | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | 1 | — | — | — | — | 1 |
| Dry eye syndromes | D015352 | — | H04.12 | 1 | — | — | — | — | 1 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | 1 | — | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Isoproterenol |
| INN | isoprenaline |
| Description | Isoprenaline is a secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders. It has a role as a sympathomimetic agent, a beta-adrenergic agonist, a bronchodilator agent and a cardiotonic drug. It is a member of catechols, a secondary amino compound and a secondary alcohol. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)c1ccc(O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 7683-59-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL434 |
| ChEBI ID | 64317 |
| PubChem CID | 3779 |
| DrugBank | DB01064 |
| UNII ID | L628TT009W (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB2
ADRB2
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Isoproterenol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 55,435 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
405 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use